Cerebrolysin
Clinical TrialsCerebrolysin
A mixture of low molecular weight neuropeptides derived from porcine brain. Researched for Alzheimer's disease, stroke recovery, and traumatic brain injury.
Dose
10-50 mL per day
Route
IV infusion, Intramuscular
Cycle
10-20 days
Storage
Not applicable (solution)
What is Cerebrolysin?
Cerebrolysin is a porcine brain-derived peptide mixture characterized by its low molecular weight neuropeptides. It is extensively researched for its neurotrophic and neuroprotective properties. Research suggests it mimics the action of endogenous neurotrophic factors like BDNF and NGF, promoting neuronal survival, differentiation, and synaptic plasticity. It has been investigated in various neurological conditions including Alzheimer's disease, stroke, and traumatic brain injury, with research focusing on its potential to improve cognitive function, reduce neuronal damage, and support recovery.
Key Benefits
- Neuroprotection
- Cognitive improvement in Alzheimer's research
- Stroke recovery support
- TBI research
- BDNF-like effects
Mechanism of Action
- Complex neuropeptide mixture
- BDNF and NGF-like activity
- Anti-apoptotic effects in neurons
- Reduces oxidative stress in brain
Best For
- Neurological injury research
- Alzheimer's research
- Cognitive rehabilitation research
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
Mixture of low molecular weight neuropeptides (generally below 10,000 Da)
Length
Variable
Type
Neuropeptide mixture
Amino acid sequence
Variable mixture
Cerebrolysin is a complex mixture of low-molecular-weight neuropeptides and amino acids derived from porcine brain. It does not have a single, defined amino acid sequence.
Pharmacokinetics
Time to peak
Not precisely defined due to complex mixture and varying administration routes
Half-life
Not established as a single value — it is a peptide mixture whose fractions clear within hours
Time to clear
Not precisely defined due to complex mixture and varying administration routes
Half-life is unknown for the mixture as a whole, as it comprises various peptides and amino acids with different pharmacokinetic properties.
Research Indications
Alzheimer's Disease Research
Extensively researched for its potential to improve cognitive function, memory, and daily living activities in patients with Alzheimer's disease. Studies suggest neuroprotective effects and promotion of neuronal plasticity.
Vascular Dementia
Investigated for improving cognitive deficits and overall clinical status in individuals with vascular dementia, often showing benefits in executive function and attention.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute Ischemic Stroke Recovery | 30-50 mL | Daily for 10-21 days | Intravenous infusion (diluted in 100-250 mL saline) |
| Mild to Moderate Alzheimer's Disease | 10-30 mL | Daily for 20 days, followed by a 2-month break, then repeat cycles | Intravenous infusion (diluted) or Intramuscular (up to 5 mL per site) |
| Traumatic Brain Injury (Moderate to Severe) | 20-50 mL | Daily for 10-14 days | Intravenous infusion (diluted) |
| Vascular Dementia | 10-20 mL | Daily for 10-20 days, often with repeat cycles after a break | Intravenous infusion (diluted) |
| Cognitive Impairment (general research) | 5-10 mL | Daily for 10-20 days, with potential for maintenance cycles | Intramuscular or slow intravenous infusion (diluted) |
For intravenous administration, Cerebrolysin is typically diluted in saline solution (e.g., 0.9% NaCl) and administered as a slow infusion over a period of 15-60 minutes, depending on the dose.
Peptide Interactions
- Use Caution
Antidepressants (especially MAO inhibitors)
Some research suggests Cerebrolysin may potentiate the effects of antidepressants, particularly MAO inhibitors, potentially leading to adverse reactions. Concomitant use should be carefully monitored in research settings.
- Avoid
Balanced Amino Acid Solutions
Cerebrolysin is composed of amino acids and peptides. Mixing it with balanced amino acid solutions in infusion bottles may lead to additive effects or interactions that are not well-characterized, potentially altering efficacy or safety.
- Monitor Combination
Certain Vitamins (e.g., Vitamin B complex)
While not generally contraindicated, the complex nature of Cerebrolysin means its interaction with high doses of certain vitamins, especially those affecting neurological pathways, should be monitored in research contexts.
- Use Caution
Alcohol
Alcohol can have neurotoxic effects and impair cognitive function, which may counteract the potential neuroprotective and cognitive-enhancing effects being researched for Cerebrolysin. Avoidance is typically recommended in research.
- Monitor Combination
Hypnotics/Sedatives
There is limited specific interaction data, but given Cerebrolysin's CNS effects, it is prudent to monitor subjects if hypnotics or sedatives are concurrently used in research protocols.
How to Reconstitute
- 1Verify the concentration and volume of the Cerebrolysin ampoule.
- 2For intravenous administration, draw the required dose of Cerebrolysin from the ampoule using a sterile syringe.
- 3Dilute the drawn Cerebrolysin in an appropriate infusion solution (e.g., 0.9% sodium chloride, Ringer's solution, 5-10% glucose solution) to the recommended volume for infusion.
- 4Ensure the final solution is clear and free of particulate matter before administration.
- 5Administer the diluted solution via slow intravenous infusion over the specified duration.
What to Expect
- Weeks 1-2: Initial observations may include subtle changes in mood or energy. For acute conditions like stroke, early neurological stabilization might be noted in research.
- Weeks 3-4: Some cognitive improvements, such as enhanced memory or focus, might be reported in studies on chronic conditions like Alzheimer's. Research on stroke recovery may indicate improved motor function.
- Weeks 5-8 (after completing a cycle): More noticeable benefits in cognitive domains or functional recovery may become apparent, consistent with its proposed neurotrophic effects.
- Months 2-3 (during break between cycles): Observed improvements may stabilize or slowly decline, prompting consideration of another research cycle if benefits were noted.
- Subsequent cycles: Continued research cycles may lead to sustained or further enhanced benefits, particularly in neurodegenerative research.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Dizziness | Uncommon | Mild |
| Nausea | Uncommon | Mild |
| Allergic reactions | Rare | Moderate |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.